Key result
Aminopeptidase A inhibitors, such as RB150, block brain angiotensin III formation and normalize blood pressure in hypertensive rats, and are currently in Phase Ib clinical trials.
Why the study?
Do aminopeptidase A inhibitors reduce blood pressure in hypertensive animal models?
Population
Hypertensive animal models (DOCA-salt rats or spontaneously hypertensive rats [SHRs])
Design
Review
Authors
Loading...
Hypothesis-generating for brain RAS inhibition in hypertension; should not yet change clinical practice.
Do aminopeptidase A inhibitors reduce blood pressure in hypertensive animal models?
Aminopeptidase A inhibitors like RB150 represent a novel class of centrally acting antihypertensive agents that effectively normalize blood pressure in preclinical models.
Gao et al. (2014) conducted a review in Hypertension. Aminopeptidase A inhibitors (RB150) was evaluated. Aminopeptidase A inhibitors, such as RB150, block brain angiotensin III formation and normalize blood pressure in hypertensive rats, and are currently in Phase Ib clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: